• Careers
  • Investors
  • News
    • Press Releases
    • Recent Media
    • Scientific Publications
  • Who We Are
    • About Nanoscope
    • Leadership
    • Management Team
    • Board of Directors
    • Visionary Advisory Committee
  • The Science
  • Our Future
    • Pipeline
    • Disease Targets
    • Clinical Trials for RP
    • Clinical Trials for Stargardt
  • For Patients
    • Hear from Patients
    • Patient & Caregiver Resources
  • Contact

Recent Posts

  • Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting
  • Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases – A First for a Retinal Gene Therapy
  • Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration
  • Nanoscope Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
  • Nanoscope Therapeutics’ MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress

Recent Comments

    Archives

    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • May 2023
    • April 2023
    • March 2023
    • January 2023
    • October 2022
    • September 2022
    • July 2022
    • May 2022
    • February 2022
    • January 2022
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • October 2020
    • July 2020
    • June 2020
    • September 2018
    • October 2017

    Categories

    • Home Page
    • Nanoscope in the News
    • Nanoscope Press Release
    • Presentations
    • Publications

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    May 12, 2025 in Presentations

    ASGCT 2025: Human Retinal Cell Delivery of a Bioengineered Synthetic Protein Sensitive to Multiple Wavelengths of Light in Patients With Stargardt Disease

    Nanoscope Therapeutics 0 Like Post Comments Off on ASGCT 2025: Human Retinal Cell Delivery of a Bioengineered Synthetic Protein Sensitive to Multiple Wavelengths of Light in Patients With Stargardt Disease

    Presented by Dr. Vinit Mahajan, Professor of Ophthalmology, Stanford University

    Read More
    NSCOPE_nu_Logo_Horizontal_white

    FOLLOW US

    Linkedin Instagram Facebook X-twitter

    Contact Us
    Terms of Use
    Expanded Access Policy

    ©2021-2026 Nanoscope Therapeutics, Inc.

    This website uses cookies to improve your experience. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit the Cookie Settings to provide a controlled consent. Cookie settings Accept
    Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled

    This is an necessary category.

    Non Necessary

    This is an non-necessary category.

    Save & Accept